Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Protocadherin 17 promoter methylation in tumour tissue from patients with bladder transitional cell carcinoma.

Wang XB, Lin YL, Li ZG, Ma JH, Li J, Ma JG.

J Int Med Res. 2014 Apr;42(2):292-9. doi: 10.1177/0300060513504364. Epub 2014 Feb 24.

PMID:
24567353
2.

Protocadherin-17 promoter methylation in serum-derived DNA is associated with poor prognosis of bladder cancer.

Luo ZG, Li ZG, Gui SL, Chi BJ, Ma JG.

J Int Med Res. 2014 Feb;42(1):35-41. doi: 10.1177/0300060513504705. Epub 2013 Dec 23.

PMID:
24366498
3.

RUNX3 methylation as a predictor for disease progression in patients with non-muscle-invasive bladder cancer.

Yan C, Kim YW, Ha YS, Kim IY, Kim YJ, Yun SJ, Moon SK, Bae SC, Kim WJ.

J Surg Oncol. 2012 Mar 15;105(4):425-30. doi: 10.1002/jso.22087. Epub 2011 Aug 30.

PMID:
22311819
4.

The clinical significance of PCDH10 promoter methylation in patients with bladder transitional cell carcinoma.

Lin YL, Li ZG, Guan TY.

Urol Int. 2013;90(2):219-24. doi: 10.1159/000345053. Epub 2012 Nov 16.

PMID:
23171734
5.

Clinical and prognostic significance of protocadherin-10 (PCDH10) promoter methylation in bladder cancer.

Lin YL, Li ZG, He ZK, Guan TY, Ma JG.

J Int Med Res. 2012;40(6):2117-23.

PMID:
23321168
6.

Clinical significance of protocadherin-8 (PCDH8) promoter methylation in bladder cancer.

Lin YL, Ma JH, Luo XL, Guan TY, Li ZG.

J Int Med Res. 2013 Feb;41(1):48-54. doi: 10.1177/0300060513475571. Epub 2013 Jan 23. Erratum in: J Int Med Res. 2014 Oct;42(5):1189. Retraction in: J Int Med Res. 2014 Oct;42(5):1189.

PMID:
23569129
7.
8.

Hypermethylation of E-cadherin, p16, p14, and RASSF1A genes in pathologically normal urothelium predict bladder recurrence of bladder cancer after transurethral resection.

Lin HH, Ke HL, Wu WJ, Lee YH, Chang LL.

Urol Oncol. 2012 Mar-Apr;30(2):177-81. doi: 10.1016/j.urolonc.2010.01.002. Epub 2010 Aug 25.

PMID:
20800513
9.

Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.

Kim JS, Chae Y, Ha YS, Kim IY, Byun SS, Yun SJ, Kim WJ.

Clin Genitourin Cancer. 2012 Jun;10(2):114-20. doi: 10.1016/j.clgc.2011.12.003. Epub 2012 Feb 28.

PMID:
22382007
10.

Clinical significance of protocadherin 8 (PCDH8) promoter methylation in non-muscle invasive bladder cancer.

Lin YL, Wang YL, Ma JG, Li WP.

J Exp Clin Cancer Res. 2014 Aug 22;33:68. doi: 10.1186/s13046-014-0068-7.

11.

Regularly methylated novel pro-apoptotic genes associated with recurrence in transitional cell carcinoma of the bladder.

Christoph F, Weikert S, Kempkensteffen C, Krause H, Schostak M, Miller K, Schrader M.

Int J Cancer. 2006 Sep 15;119(6):1396-402.

12.

Hypermethylation of an E-cadherin (CDH1) promoter region in high grade transitional cell carcinoma of the bladder comprising carcinoma in situ.

Horikawa Y, Sugano K, Shigyo M, Yamamoto H, Nakazono M, Fujimoto H, Kanai Y, Hirohashi S, Kakizoe T, Habuchi T, Kato T.

J Urol. 2003 Apr;169(4):1541-5.

PMID:
12629411
13.
14.

Frequency of P16INK4a and P14ARF genes methylation and its impact on bladder cancer cases in north Indian population.

Ali Hosseini S, Sobti RC, Malekzadeh K, Singh SK, Joshi K.

Dis Markers. 2010;28(6):361-8. doi: 10.3233/DMA-2010-0716.

15.

Methylation patterns of Rb1 and Casp-8 promoters and their impact on their expression in bladder cancer.

Malekzadeh K, Sobti RC, Nikbakht M, Shekari M, Hosseini SA, Tamandani DK, Singh SK.

Cancer Invest. 2009 Jan;27(1):70-80. doi: 10.1080/07357900802172085.

PMID:
19160091
16.

Epigenetic inactivation of KLF4 is associated with urothelial cancer progression and early recurrence.

Li H, Wang J, Xiao W, Xia D, Lang B, Wang T, Guo X, Hu Z, Ye Z, Xu H.

J Urol. 2014 Feb;191(2):493-501. doi: 10.1016/j.juro.2013.08.087. Epub 2013 Sep 7.

PMID:
24018236
17.

Aberrant methylation of protocadherin 17 and its prognostic value in pediatric acute lymphoblastic leukemia.

Uyen TN, Sakashita K, Al-Kzayer LF, Nakazawa Y, Kurata T, Koike K.

Pediatr Blood Cancer. 2017 Mar;64(3). doi: 10.1002/pbc.26259. Epub 2016 Sep 19.

PMID:
27643535
18.

The prognostic value of P-cadherin in non-muscle-invasive bladder cancer.

Wang P, Lin SL, Zhang LH, Li Z, Liu Q, Gao JX, Liu DM, Bo JJ, Huang YR.

Eur J Surg Oncol. 2014 Mar;40(3):255-9. doi: 10.1016/j.ejso.2013.12.018. Epub 2014 Jan 2.

PMID:
24429027
19.

Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma.

Dhawan D, Hamdy FC, Rehman I, Patterson J, Cross SS, Feeley KM, Stephenson Y, Meuth M, Catto JW.

J Pathol. 2006 Jul;209(3):336-43.

PMID:
16639696
20.

Promoter hypermethylation in tumour suppressor genes shows association with stage, grade and invasiveness of bladder cancer.

Jarmalaite S, Jankevicius F, Kurgonaite K, Suziedelis K, Mutanen P, Husgafvel-Pursiainen K.

Oncology. 2008;75(3-4):145-51. doi: 10.1159/000158665. Epub 2008 Sep 29.

PMID:
18824877

Supplemental Content

Support Center